Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice

European Journal of Pharmacology

Volumn 601, Issue 1-3, 2008, Pages 129-135

  Hirasawa, Yasushi ^a,b   Matsui, Yukari ^b   Ohtsu, Shoko ^b   Yamane, Kazusuke ^b   Toyoshi, Tohru ^b   Kyuki, Kohei ^b   Sakai, Takayuki ^a   Feng, Yibin ^c   Nagamatsu, Tadashi ^a  

^a MEIJO UNIVERSITY   (Japan)

^b Nihon Bioresearch Inc   (Japan)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aggregated protein; Alpha glucosidase inhibitor; Diabetes; Glomeruli; Insulin; KK Ay mice; Pioglitazone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; VOGLIBOSE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLOMERULUS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HYPERGLYCEMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; KIDNEY GLOMERULUS; LYSINE; MALE; MICE; MICE, INBRED ICR; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; THIAZOLIDINEDIONES;

EID: 56949085461     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.015     Document Type: Article

References (33)

1. Axe S.R., Katz S.M., and Lavine R. Immunoglobulin deposition in the microvasculature of the streptozotocin-induced diabetic rat. Lab. Invest. 45 (1981) 229-233
2. Bhatwadekar A.D., and Ghole V.S. Rapid method for the preparation of an AGE-BSA standard calibrator using thermal glycation. J. Clin. Lab. Anal. 19 (2005) 11-15
3. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 37 (1998) 586-600
4. Brizzi M.F., Dentelli P., Rosso A., Calvi C., Gambino R., Cassader M., Salvidio G., Deferrari G., Camussi G., Pegoraro L., Pagano G., and Cavallo-Perin P. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J. 18 (2004) 1249-1251
5. Chujo K., Shima K., Tada H., Oohashi T., Minakuchi J., and Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J. Med. Investig. 53 (2006) 223-228
6. Danze P.M., Tarjoman A., Rousseaux J., Fossati P., and Dautrevaux M. Evidence for an increased glycation of IgG in diabetic patients. Clin. Chim. Acta 166 (1987) 143-153
7. Figarola J.L., Scott S., Loera S., Tessler C., Chu P., Weiss L., Hardy J., and Rahbar S. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46 (2003) 1140-1152
8. Gallicchio M.A., McRobert E.A., Tikoo A., Cooper M.E., and Bach L.A. Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. J. Am. Soc. Nephrol. 17 (2006) 414-421
9. Herz M., Johns D., Reviriego J., Grossman L.D., Godin C., Duran S., Hawkins F., Lochnan H., Escobar-Jimenez F., Hardin P.A., Konkoy C.S., and Tan M.H. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther. 25 (2003) 1074-1095
10. Hirasawa Y., Muramatsu A., Suzuki Y., and Nagamatsu T. Insufficient expression of cyclooxygenase-2 protein is associated with retarded degradation of aggregated protein in diabetic glomeruli. J. Pharmacol. Sci. 102 (2006) 173-181
11. Ishida H., Takizawa M., Ozawa S., Nakamichi Y., Yamaguchi S., Katsuta H., Tanaka T., Maruyama M., Katahira H., Yoshimoto K., Itagaki E., and Nagamatsu S. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 53 (2004) 488-494
12. Ishizaki M., Masuda Y., Fukuda Y., Yamanaka N., Masugi Y., Shichinohe K., and Nakama K. Renal lesions in a strain of spontaneously diabetic WBN/Kob rats. Acta Diabetol. Lat. 24 (1987) 27-35
13. Ito T., Tanimoto M., Yamada K., Kaneko S., Matsumoto M., Obayashi K., Hagiwara S., Murakoshi M., Aoki T., Wakabayashi M., Gohda T., Funabiki K., Maeda K., Horikoshi S., and Tomino Y. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 11 (2006) 29-35
14. Koyama M., Wada R., Mizukami H., Sakuraba H., Odaka H., Ikeda H., and Yagihashi S. Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor. Metabolism 49 (2000) 347-352
15. Lu C., He J.C., Cai W., Liu H., Zhu L., and Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11767-11772
16. Makita Z., Bucala R., Rayfield E.J., Friedman E.A., Kaufman A.M., Korbet S.M., Barth R.H., Winston J.A., Fuh H., Manogue K.R., et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343 (1994) 1519-1522
17. Mitsuhashi T., Nakayama H., Itoh T., Kuwajima S., Aoki S., Atsumi T., and Koike T. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 42 (1993) 826-832
18. Nagamatsu T., Hirasawa Y., Matsui Y., Ohtsu S., Yamane K., Toyoshi T., Kyuki K., and Suzuki Y. Increase in the deposition of aggregated protein in the glomeruli of spontaneously diabetic mice. J. Pharmacol. Sci. 99 (2005) 287-293
19. Nagamatsu T., Nagao T., Koseki J., Sugiura M., Nishiyama T., and Suzuki Y. Involvement of prostaglandin E2 in clearance of aggregated protein via protein kinase A in glomeruli. Jpn. J. Pharmacol. 85 (2001) 139-145
20. Nakamura S., Makita Z., Ishikawa S., Yasumura K., Fujii W., Yanagisawa K., Kawata T., and Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 (1997) 895-899
21. Okazaki M., Saito Y., Udaka Y., Maruyama M., Murakami H., Ota S., Kikuchi T., and Oguchi K. Diabetic nephropathy in KK and KK-Ay mice. Exp. Anim. 51 (2002) 191-196
22. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., and Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 301 (2000) 65-77
23. Satoh N., Shimatsu A., Yamada K., Aizawa-Abe M., Suganami T., Kuzuya H., and Ogawa Y. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 55 (2006) 786-793
24. Schalkwijk C.G., Ligtvoet N., Twaalfhoven H., Jager A., Blaauwgeers H.G., Schlingemann R.O., Tarnow L., Parving H.H., Stehouwer C.D., and van Hinsbergh V.W. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48 (1999) 2446-2453
25. Skolnik E.Y., Yang Z., Makita Z., Radoff S., Kirstein M., and Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 174 (1991) 931-939
26. Suzuki D. Measurement of the extracellular matrix in glomeruli from patients with diabetic nephropathy using an automatic image analyzer. Nippon Jinzo Gakkai Shi 36 (1994) 1209-1215
27. Takemoto M., Asker N., Gerhardt H., Lundkvist A., Johansson B.R., Saito Y., and Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am. J. Pathol. 161 (2002) 799-805
28. Takeuchi M., Bucala R., Suzuki T., Ohkubo T., Yamazaki M., Koike T., Kameda Y., and Makita Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59 (2000) 1094-1105
29. Tanaka Y., Uchino H., Shimizu T., Yoshii H., Niwa M., Ohmura C., Mitsuhashi N., Onuma T., and Kawamori R. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 376 (1999) 17-22
30. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., Stern D., Schmidt A.M., and D'Agati V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11 (2000) 1656-1666
31. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., and Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11704-11708
32. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., Ooka H., Satozawa N., Kawakami T., Nomura M., and Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272 (1997) 8723-8730
33. Yamamoto Y., Kato I., Doi I., Yonekura H., Ohashi S., Takeuchi M., Watanabe T., Yamagishi S., Sakurai S., Takasawa S., Okamoto H., and Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108 (2001) 261-268